H EPATITIS C T REATMENT A - T A

FDAFDSAF HEPATITIS C TREATMENT AT A GLANCE: 2024 INTRODUCTION The Hepatitis C (HCV) Treatment At a Glance tool provides an overview of the coverage of key HCV services in Massachusetts as of February 2024 in order to give health care providers quick access to basic coverage information to help inform discussions with patients about treatment. [...] The landscape of treatment for HCV has evolved considerably with the introduction of direct-acting antivirals (DAAs) in 2013 and the market entry of generic treatments in 2019. [...] Treatment with DAAs cures over 95% of patients and can be completed in as little as 8 weeks.1 The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America’s (AASLD/IDSA) guidance, Recommendations for Testing, Managing, and Treating Hepatitis C, recommends treatment with DAAs for virtually all individuals with chronic HCV infection.2 In addition, in March. [...] mailto:chlpi@law.harvard.edu MASSACHUSETTS SILVER-LEVEL QUALIFIED HEALTH PLANS The table below summarizes coverage of HCV services in the silver-level Qualified Health Plans (QHPs) available to individuals via the Massachusetts health insurance marketplace (Massachusetts. [...] As of August 1, 2016, all MassHealth beneficiaries have a right to access HCV direct-acting antivirals without restrictions related to fibrosis score, substance use abstinence, or prescriber specialty.4 If you experience treatment denials based on these criteria, please contact the Center for Health Law and Policy Innovation of Harvard Law School: chlpi@law.harvard.edu.